Cedars-Sinai to use UV light to treat coronavirus

A new ultraviolet (UV) therapy for treating the Wuhan coronavirus (COVID-19) is coming to a hospital near you.

Developed by Cedars-Sinai hospital in Los Angeles, Healight Platform Technology, or “healight,” has been exclusively licensed to Aytu BioScience, Inc. for worldwide commercial development and release, which means that hospitals everywhere are soon to adopt it.

Touted as a potential “first-in-class treatment for coronavirus and other respiratory infections,” healight utilizes proprietary methods of administering intermittent UVA light using a novel endotracheal medical device. Pre-clinical findings show that it has the potential to help eradicate the spread of the Wuhan coronavirus (COVID-19), as well as “a wide range of viruses and bacteria, inclusive of coronavirus.”

With Dr. Mark Pimentel, MD leading the research, a team from the Medically Associated Science and Technology (MAST) Program at Cedars-Sinai has been working on healight since 2016, and a growing body of evidence shows efficacy as both an antiviral and antibacterial treatment.

The group has been in talks with the United States Food and Drug Administration (FDA) about developing a near-term path that would enable early use of healight technology to treat Wuhan coronavirus (COVID-19) patients suffering in intensive care units (ICUs). Healight may also be useful in treating ventilator associated pneumonia, or VAP.

“Our team has shown that administering a specific spectrum of UV-A light can eradicate viruses in infected human cells (including coronavirus) and bacteria in the area while preserving healthy cells,” Dr. Pimentel is quoted as saying.

Dr. Ali Rezaie, M.D., another one of the inventors behind healight, further contends that extensive study into the technology has verified its usefulness in a range of clinical applications.

“Based on our findings we believe this therapeutic approach has the potential to significantly impact the high morbidity and mortality of coronavirus-infected patients and patients infected with other respiratory pathogens. We are looking forward to partnering with Aytu BioScience to move this technology forward for the benefit of patients all over the world,” she says.

Be sure to listen to The Health Ranger Report below as Mike Adams, the Health Ranger, talks about the mainstream media, including sources on the “left” and “right,” are herding the masses towards global vaccine mandates:

UV light is already used to disinfect hospital rooms, equipment

Aytu, Cedars-Sinai, and the FDA are all said to be working together towards forging a plan for the expedited regulatory approval of healight, which is urgently needed, they claim, to address the continued scourge of the Wuhan coronavirus (COVID-19).

Those with critical illnesses associated with the Wuhan coronavirus (COVID-19) could benefit from a treatment that, especially compared to pharmaceuticals and vaccines, is minimally invasive and more than likely safe.

Many hospitals are already using UV light to clean surfaces and disinfect rooms where Wuhan coronavirus (COVID-19) patients were treated. Extending this technology to direct treatment of Wuhan coronavirus (COVID-19) patients would seem to be the logical next step.

Since natural UV light from the sun is fully capable of destroying harmful bacteria on skin, as well as viruses and other microbes, similar benefits could be had from artificial UV rays generated by medical devices, which is what Aytu and Cedars-Sinai hope can be widely implemented across the world.

“This first-in-class technology has the potential to be a game changer for clinicians treating patients infected with coronavirus and other respiratory conditions, and our team is working tirelessly alongside the Cedars-Sinai team to determine the safety and effectiveness of this device in humans,” says Josh Disbrow, Chairman and CEO of Aytu BioScience.

More of the latest news about the Wuhan coronavirus (COVID-19) is available at Pandemic.news.

Sources for this article include:

Yahoo.com

NaturalNews.com